391 pharmaceutical companies posted their transcripts for the first half of the year!

Up to now, a total of 391 pharmaceutical companies in A-shares have disclosed their performance in the first half of 2021, and more than 70% of companies' performance (revenue, net profit) has both increased
.

Among them, 20 companies have a revenue of more than 10 billion yuan, Shanghai Pharmaceuticals has broken through the 100 billion yuan mark, ranking first, Jointown, Baiyunshan, etc.

Net profit TOP10: Zhifei, Mindray, Hengrui.
.
.
more than 2 billion

Net profit TOP10: Zhifei, Mindray, Hengrui.
.
.
more than 2 billion

TOP10 net profit of pharmaceutical companies in the first half of 2021 (unit: 100 million yuan)

From the perspective of net profit, there were 13 pharmaceutical companies in the first half of this year with a scale of more than 2 billion yuan.
Among them, Ingram Medical and Zhifei Biotechnology exceeded the 5 billion yuan mark.
Create a new high
.

In the same period of 2020, there are only 5 companies with a net profit of more than 2 billion yuan, namely Mindray Medical, Hengrui Pharmaceutical, Yunnan Baiyao, Shanghai Pharmaceutical and Xinhecheng

On August 30, Zhifei Biological disclosed its 2021 semi-annual report, with a net profit of 5.
491 billion yuan, a year-on-year increase of 264.
94%, far exceeding the 2020 full-year net profit of 3.
301 billion yuan
.

As of the first half of the year, Zhifei Bio has 10 products on sale, and 1 product is used for emergency use, including vaccine products to prevent infectious diseases such as meningitis, cervical cancer, and pneumonia, covering those that provide effective solutions for the diagnosis, prevention, and treatment of tuberculosis infection.

As a leading CRO company, WuXi AppTec has attracted much attention in the industry
.

In the first half of this year, WuXi AppTec's net profit hit a new high, surpassing 2 billion yuan for the first time, a year-on-year increase of 55.

Gross profit margin TOP10: sci-tech innovation board pharmaceutical companies won the "first brother" throne

Gross profit margin TOP10: sci-tech innovation board pharmaceutical companies won the "first brother" throne

TOP10 gross profit margin of pharmaceutical companies in the first half of 2021

In terms of gross profit margin, 18 pharmaceutical companies have gross profit margins of more than 90%
.

Iris from the Science and Technology Innovation Board won the "Big Brother" throne; Biotech followed closely behind with its strong growth rate, and Wu Biotech and Yiqiao Shenzhou also exceeded 95%

In December last year, Iris officially landed on the Science and Technology Innovation Board, and its gross profit margin was as high as 98.
70% in the first half of this year, winning the "first brother" throne
.

It is understood that Alis is an innovative drug company focusing on the field of tumor treatment.

Biotech's gross profit margin has steadily increased since its listing, from 86.
24% in the first half of 2020 to 96.
33% in the first half of 2021
.

As of the first half of this year, the company has one product (Adalimumab Injection (Glerli)) on the market, which is the first adalimumab biosimilar drug approved for marketing in China

In the first half of the year, our revenue and net profit both rose by more than 30%, with revenue of 348 million yuan, net profit of 147 million yuan, and gross profit margin of 95.
66%.
The leading product "Dust Mite Drops" is the company's main source of revenue.
The sales revenue of this product largely determines the company's profitability
.

Regarding the relatively concentrated risk of leading products, Wu Biotech stated that the company’s new product "Artemisia annua pollen allergen sublingual drops" was approved in January this year, but it will take some time for the product to be sold on a large scale.

Revenue TOP10: Shanghai Pharmaceuticals surpassed 100 billion, Jointown, Baiyunshan.
.
.
a new high

Revenue TOP10: Shanghai Pharmaceuticals surpassed 100 billion, Jointown, Baiyunshan.
.
.
a new high

TOP10 revenue of pharmaceutical companies in the first half of 2021 (unit: 100 million yuan)

From the perspective of revenue, 20 companies including Shanghai Pharmaceuticals, Jointown, Baiyunshan, and Sinopharm have exceeded 10 billion yuan in scale
.
Among them, Shanghai Pharmaceuticals broke through the 100 billion yuan mark, ranking first; Jointown and Baiyunshan also reached new highs
.
In the same period of 2020, there are 16 companies with revenues exceeding 10 billion yuan
.

On August 31, Shanghai Pharmaceuticals released the 2021 semi-annual report, operating revenue of 105.
2 billion yuan, a year-on-year increase of 20.
73%
.
The revenue of the pharmaceutical industry was 12.
602 billion yuan, a year-on-year increase of 7.
94%; the pharmaceutical business revenue was 92.
635 billion yuan, a year-on-year increase of 22.
71%
.
Shanghai Pharmaceuticals pointed out in the semi-annual report that the economy continued to recover steadily in the first half of the year, market demand continued to rebound, economic development was stable and positive, and the company maintained a good operating trend
.
In the pharmaceutical industry, the sales revenue of 60 key products increased by 11.
94% year-on-year, and the sales revenue of the top five key products doubled from the same period last year; the sales revenue of the Chinese medicine sector increased by 18% year-on-year
.
In terms of pharmaceutical commerce, it has consolidated its leading position in imports and actively expanded its innovative business.
The pharmaceutical commercial network covers 24 provinces and cities across the country, creating a modern pharmaceutical distribution system with a high degree of intensive and informatization
.

Jointown's revenue reached a record high in the first half of this year, surpassing the scale of 60 billion yuan, a year-on-year increase of 20.
70%
.
Regarding the rapid growth in performance, Jointown Express said that on the one hand, the commercial distribution business strengthens the strategic cooperation of core distribution and top 100 chain stores, and continues to promote core e-commerce projects; on the other hand, the general agent general sales and self-produced business seize the good business opportunities of expansion and actively Introduce and vigorously promote high-quality general agent general sales products and self-produced products of the pharmaceutical industry, and optimize product structure and marketing strategies
.

A-share pharmaceutical companies' performance in the first half of 2021

Source: Oriental Fortune.
com, Announcement of Listed Companies

Please correct me if there are any errors or omissions
.